Sibrafiban

Identifiers
IUPAC name [Z]-(S)-[[1-[2-[[4-(amino-hydroxyiminomethyl)-benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxyl]-acetic ethyl ester
CAS Number	170094-62-9 Y
PubChem CID	5491394
ChemSpider	4590509
UNII	YUE443B0NF
KEGG	D05834
ChEMBL	ChEMBL435176
CompTox Dashboard (EPA)	DTXSID90938247
Chemical and physical data
Formula	C20H28N4O6
Molar mass	420.466 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCOC(=O)COC1CCN(CC1)C(=O)[C@H](C)NC(=O)c2ccc(cc2)C(=N)NO
InChI InChI=1S/C20H28N4O6/c1-3-29-17(25)12-30-16-8-10-24(11-9-16)20(27)13(2)22-19(26)15-6-4-14(5-7-15)18(21)23-28/h4-7,13,16,28H,3,8-12H2,1-2H3,(H2,21,23)(H,22,26)/t13-/m0/s1 Key:WBNUCLPUOSXSNJ-ZDUSSCGKSA-N

Sibrafiban (Ro 48–3657, proposed brand name Xubix) is the double prodrug of Ro-44-3888, which is a platelet aggregation inhibitor. It was being developed for secondary prevention of arterial thrombosis following unstable angina pectoris and acute myocardial infarction (MI).^[1] On August 6, 1999, Hoffmann-La Roche announced that the preliminary results from Phase III clinical trials had not shown that sibrafiban was better than aspirin in preventing recurrent ischemic events in patients with acute coronary syndrome. The development of sibrafiban was terminated.

See also[edit]

• Tirofiban

References[edit]